Category Archives: Stell Cell Research

Election 2020: Californias ballot initiative system isnt working. – Vox.com

Finding the best ways to do good.

I live in California. And three weeks before the election, the people in my quarantine bubble sat down in our living room for a nine-hour research project: figuring out how to vote.

Not for our elected representatives or for president, but on kidney dialysis regulations and stem-cell medical research funding and whether to uphold a law passed by the legislature replacing cash bail with a risk assessment system and nine more propositions after those. My ballot was six pages long, many of them on issues Id never thought about before and, after a few frustrating hours figuring out how to vote, will never think about again.

Direct democracy can be a profound and important tool for political change, and 2020 had many examples of that. In several states, voters decriminalized drugs from marijuana to mushrooms sending a powerful message to lawmakers that their constituents are done with the war on drugs. Ive written in past years that voters are way ahead of state legislatures on banning animal cruelty. Americas electoral system definitely benefits from a place for voters to directly weigh in on issues. (My colleague Sigal Samuel has a rundown of the ballot initiatives that we should cheer in todays edition of the Future Perfect newsletter. Subscribe!)

But what it doesnt benefit from is a system like Californias, where ballots get padded out and weighted down with unclearly written ballot propositions on a dozen niche issues. Many people have been frustrated by these problems on their ballots, but California where voters have been asked to simultaneously entertain abolishing and expediting the death penalty, to weigh dueling propositions about plastic bags, to advise the state legislature to overturn US Supreme Court decisions (it cannot do that), and now, on two different occasions, to weigh in on the proper running of dialysis clinics leads the pack.

A system that funnels lots of issues, both big and small, directly to the voters leads to bad policy judgments, because under-informed voters dont have time to research and form opinions on all the issues. It leads to a handicapped legislature that cant do its job, because large sections of state law are untouchable. (In California, for instance, the legislature has to send many propositions to voters because other propositions have prohibited them from legislating directly.) When a voter-approved initiative is unclearly worded, it can cause years of uncertainty because the issue cant easily be sent back to the voters to adjust the wording.

But just because how we run ballot propositions today is a problem doesnt mean we have to give them up altogether. There is a way we can make direct democracy work.

Lets say that you dislike the work your state legislature is doing. In 26 US states and Washington, DC, you have the power to ask voters to pass laws themselves through a ballot initiative.

There are, broadly, three categories of ballot initiatives available in the states that have a citizen initiative process. In the first, citizens draw up a proposed law and put it on the ballot. If other citizens approve it, it becomes a law. In the second, citizens who disapprove of a law the legislature passed put it on the ballot to try to repeal it (called a veto referendum). In the third, citizens propose, and vote on, a change to the state constitution.

Some states only allow some of these types of initiatives, and some dont allow citizen initiatives at all. Maryland and New Mexico, for example, only allow veto referendums; Utah, Wyoming, Washington, Maine, Alaska, and Idaho allow citizens to put forth initiatives, but not constitutional amendments. Illinois, Mississippi, and Florida allow constitutional amendments but not initiatives.

The details of the process to put a new law, a veto referendum, or a constitutional amendment on the ballot varies from state to state, but in general, proponents file their proposed initiative with the state and then start collecting signatures for it. If they collect enough signatures, it goes on the ballot for the next statewide election. If it wins over enough voters at the election, it becomes a law.

Lots of important work has gotten done through ballot initiatives. But in many ways, laws passed via initiative are more problematic than laws passed by the legislature. Because they are not written by professional legislators, they are often unclearly written; many voters report being confused about what ballot initiatives they voted on will do. Many ballot measures are misleadingly structured so that a no vote represents a big, confusing change to the law, while a yes vote does nothing. There is fierce political fighting about initiatives are summarized on the ballot a process that is supposed to be apolitical, but sometimes isnt.

And while initiatives were meant to empower grassroots political movements, the system to put an initiative on the ballot is much easier for large lobbying groups to navigate, and special interest groups drive many initiatives.

In some states, like California, the sheer number of initiatives is starting to get out of hand, which worsens all of the other problems with ballot initiatives, as its easier for voters to see through one misleading proposition than through 10.

Every state does direct democracy in a different way.

But California reliably has one of the longest ballots. In 2016, there were 17 statewide initiatives. The voter guide mailed to all voters to explain them was 224 pages long.

In 2020, the threshold for initiatives to make the ballot was substantially higher (the threshold is set based on turnout in the most recent governors race, and 2018 turnout set records) and there werent as many. But voters still weighed in on bonds to pay for stem cell research, property tax changes, a repeal to the state ban on affirmative action, restoring voting rights for convicted felons, allowing 17-year-olds who will be 18 in November to vote in primaries, more property tax changes, changes to criminal sentencing, allowing rent control in more parts of the state, labor policies for ride-hailing apps, dialysis clinic regulations, a new data privacy law, and abolishing cash bail.

Those were just the statewide initiatives; voters also considered many city and countywide local initiatives. Thats 12 statewide initiatives, more than anywhere else in the country (though Colorado voters came close, with 11.)

California also had by far the most spending aimed at changing minds on ballot initiatives: $708 million in contributions, compared to $121 million in the next most-contested state. Across all 50 states, 120 ballot measures were decided on Election Day.

Californias initiative process permits all three types of resolutions (initiatives to create a new state law, initiatives to veto a state law passed through the legislative process, and initiatives to amend the constitution) and makes it much easier than many states to put an initiative on the ballot requiring just 5 percent of the number of voters who voted in the gubernatorial race in the most recent election to put an initiative on the ballot. Many states require 10 percent of the number of votes cast for governor and many states have competitive elections for governors.

Californias gubernatorial races are almost never competitive and often have very low turnout, which depresses the signature requirement further. In 2016, only 365,880 signatures were needed (in a state with 40 million people and 18 million registered voters) to add an initiative to the ballot. (High 2018 turnout raised the bar somewhat, but as a percentage of total population, its still one of Americas lowest thresholds.)

Finally, its not just easier for laws to make it onto the ballot; its also easier for them to pass. In many states amending the constitution requires a supermajority. In Florida, for example, which amended its constitution this week to raise the minimum wage, a 60 percent majority is required. In California, propositions including those amending the state constitution pass if they get more than 50 percent of the vote.

California was one of the first states that allowed citizen-driven ballot initiatives, and at first, ballot initiatives were sparse. As collecting signatures became easier, the number of California propositions has spiked especially in the last few decades. As a result, the initiative system has grown quite unwieldy and crude in ways that have perverted the initial vision, historian William Deverell at the University of Southern California said this fall.

For all of the drawbacks of ballot initiatives, the variety of different approaches to propositions in different states is a great thing one of the best examples of the state systems function as laboratories of democracy.

We now have some results from those laboratories of democracy, and they suggest that the initiative system works best when there are a manageable number of initiatives on the ballot at election time. Voter participation is higher, and voters are more able to focus their attention on a handful of meaningful, high-value issues: Should we legalize marijuana? Should we reenfranchise people who have been convicted of a crime and served their sentence? Should we change how our state votes?

When voters are snowed under with nearly a dozen propositions, including many on highly specific niche issues like kidney dialysis regulation that theyre unequipped to evaluate, participation drops, and the results become more strongly predicted by which side spent the most money probably because if voters dont have time to look things up, theyre more likely to go with what they saw on TV. The impressive successes of ballot initiatives against the war on drugs this year should have governments in every state thinking about how they can best use ballot initiatives to their full potential.

For the 14 states that dont allow any ballot initiatives, that might mean rethinking that. But for the states that allow ballot initiatives with a very low threshold, and see low participation and high voter confusion as a result, it means rethinking that, too. Promising proposals include raising the signature threshold, capping the number of propositions on the ballot, and restricting counter-propositions conflicting laws on the ballot at the same time.

Direct democracy is a part of our system because of a belief that voters deserve a direct say in how their state is run. The best implementation gives voters a few highly meaningful choices well worth their time. If we cant manage that, were not empowering voters were burdening them.

Sign up for the Future Perfect newsletter. Twice a week, youll get a roundup of ideas and solutions for tackling our biggest challenges: improving public health, decreasing human and animal suffering, easing catastrophic risks, and to put it simply getting better at doing good.

Will you help keep Vox free for all?

Millions of people rely on Vox to understand how the policy decisions made in Washington, from health care to unemployment to housing, could impact their lives. Our work is well-sourced, research-driven, and in-depth. And that kind of work takes resources. Even after the economy recovers, advertising alone will never be enough to support it. If you have already made a contribution to Vox, thank you. If you havent, help us keep our journalism free for everyone by making a financial contribution today, from as little as $3.

Read the original:
Election 2020: Californias ballot initiative system isnt working. - Vox.com

Stem Cell Therapy Market is estimated to be worth USD 8.5 Billion by 2030 – PRnews Leader

The success of approved stem cell therapies has caused a surge in interest of biopharma developers in this field; many innovator companies are currently progressing proprietary leads across different phases of clinical development, with cautious optimism

Roots Analysis has announced the addition of Global Stem Cells Market: Focus on Clinical Therapies, 20202030 (Based on Source (Allogeneic, Autologous); Origin (Adult, Embryonic); Type (Hematopoietic, Mesenchymal, Progenitor); Lineage (Amniotic Fluid, Adipose Tissue, Bone Marrow, Cardiosphere, Chondrocytes, Corneal Tissue, Cord Blood, Dental Pulp, Neural Tissue Placenta, Peripheral Blood, Stromal Cells); and Potency (Multipotent, Pluripotent)) report to its list of offerings.

There is a growing body of evidence supporting the vast applicability and superiority of treatment outcomes of stem cell therapies, compared to conventional treatment options. In fact, the unmet needs within this domain have spurred the establishment of many start-ups in recent years.

To order this 500+ page report, which features 185+ figures and 220+ tables, please visit this link

Key Market Insights

Over 280 stem cell therapies are under development, most of which are allogeneic products More than 50% of the pipeline candidates are in the mid to late phase trials (phase II and above), and allogenic therapies (majority of which are derived from the bone marrow) make up 65% of the pipeline.

70% of pipeline candidates are based on mesenchymal stem cells It is worth highlighting that the abovementioned therapies are designed to treat musculoskeletal (22%), neurological (21%) and cardiovascular (15%) disorders. On the other hand, hematopoietic stem cell-based products are mostly being evaluated for the treatment of oncological disorders, primarily hematological malignancies.

Close to 85% stem cell therapy developers are based in North America and Asia-Pacific regions Within these regions, the US, China, South Korea and Japan, have emerged as key R&D hubs for stem cell therapies. It is worth noting that majority of the initiatives in this domain are driven by small / mid-sized companies

Over 1,500 grants were awarded for stem cell research, since 2015 More than 45% of the total amount was awarded under the R01 mechanism (which supports research projects). The NCI, NHLBI, NICHD, NIDDK, NIGMS and OD emerged as key organizations that have offered financial support for time periods exceeding 25 years as well.

Outsourcing has become indispensable to R&D and manufacturing activity in this domain Presently, more than 80 industry / non-industry players, based in different regions across the globe, claim to provide contract development and manufacturing services to cater to the unmet needs of therapy developers. Examples include (in alphabetical order) Bio Elpida, Cell and Gene Therapy Catapult, Cell Tech Pharmed, GenCure, KBI Biopharma, Lonza, MEDINET, Nikon CeLL innovation, Roslin Cell Therapies, WuXi Advanced Therapies and YposKesi.

North America and Asia-Pacific markets are anticipated to capture over 80% share by 2030 The stem cell therapies market is anticipated to witness an annualized growth rate of over 30% during the next decade. Interestingly, the market in China / broader Asia-Pacific region is anticipated to grow at a relatively faster rate.

To request a sample copy / brochure of this report, please visit this link

Key Questions Answered

The USD 8.5 billion (by 2030) financial opportunity within the stem cell therapies market has been analyzed across the following segments:

The report features inputs from eminent industry stakeholders, according to whom stem cell therapies are currently considered to be a promising alternatives for the treatment of a myriad of disease indications, with the potential to overcome challenges associated with conventional treatment options. The report includes detailed transcripts of discussions held with the following experts:

The research covers brief profiles of several companies (including those listed below); each profile features an overview of the company, financial information (if available), stem cell therapy portfolio and an informed future outlook.

For additional details, please visit https://www.rootsanalysis.com/reports/view_document/stem-cells-market/296.html

or email [emailprotected]

You may also be interested in the following titles:

Contact:

Gaurav Chaudhary +1 (415) 800 3415 +44 (122) 391 1091 [emailprotected]

Visit link:
Stem Cell Therapy Market is estimated to be worth USD 8.5 Billion by 2030 - PRnews Leader

Cancer Stem Cell Therapeutics Market Outlooks 2020: Size, Cost Structures, Growth rate and Industry Analysis to 2027 – Eurowire

Cancer Stem Cell Therapeutics Market Report

The research study on the Global Cancer Stem Cell Therapeutics Market is a thorough investigation of the value and supply chain of the market and offers all-inclusive data about the industry. The report also covers insightful information about pricing, cost, value, capacity, gross revenue, and profit margins with reference to historical analysis and forecast estimation. The report also strives to identify demands and trends in different sectors of the Cancer Stem Cell Therapeutics market in major geographies of the world.

The Cancer Stem Cell Therapeutics market has witnessed dynamic changes in trends and demands owing to the ongoing COVID-19 pandemic. The report provides a detailed outlook on how the pandemic has affected the key segments of the Cancer Stem Cell Therapeutics industry. The report includes an in-depth impact analysis of the COVID-19 pandemic on the overall Cancer Stem Cell Therapeutics industry and covers a futuristic impact scenario.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/1414

The report studies the market dynamics to identify and scrutinize the strategic initiatives and tactics undertaken by the industry players in order to gain a robust footing in the market and to achieve a substantial global position. It provides exhaustive analysis and imparts insightful data to help the readers understand the Cancer Stem Cell Therapeutics industry in detail and gain a competitive advantage over other players. The report also provides strategic recommendations to new and emerging players to help them formulate better entry and investment strategies.

The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies. The key players studied in the report include:

Merck KGA, LONZA Group AG, Novartis, Osiris Therapeutics, Pfizer, Pfizer, Stemline Therapeutics Inc., STEMCELL Technologies, and Thermo Fischer Scientific Inc.

The report offers a comprehensive analysis of the Cancer Stem Cell Therapeutics market inclusive of product portfolio, categories, applications, and a comprehensive analysis of the value chain structure. The study investigates several factors influencing the growth of the market and provides a competitive advantage to the readers.

The Cancer Stem Cell Therapeutics market report is an investigative study that provides insights into opportunities, limitations, and barriers encountered by the companies that influence or hinder the growth of the industry. Overall the report provides valuable information and an overview of the market scenario to gain a better understanding of the market.

Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/1414

Treatment Type: (Revenue, USD Million; 20162026)

Disease Type: (Revenue, USD Million; 20162026)

Application: (Revenue, USD Million; 20162026)

End Use: (Revenue, USD Million; 20162026)

The report covers an extensive regional analysis and market estimation in each region and covers key geographical regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa.

To read more about the report, visit @ https://www.reportsanddata.com/report-detail/cancer-stem-cell-therapeutics-market

Key Point Summary of the Report:

Thank you for reading our report. For further queries, please connect with us to know more about the report and its customization. Our team will ensure the report is customized accurately to meet your requirements.

Take a look at other reports from Reports and Data on PR Newswire:

Spine Biologics Market: Spine Biologics Market to Reach USD 2,629.6 Million By 2027 | CAGR: 3.9%

Isobutanol Market: Isobutanol Market to Reach USD 1555.8 Million By 2027 | CAGR: 6.4%

Hematology Analyzers and Reagents Market: Hematology Analyzers and Reagents Market to Reach USD 12.10 Billion By 2027

Isobutanol Market: Isobutanol Market to Reach USD 1555.8 Million By 2027 | CAGR: 6.4%

About Us:

Our in-house experts assist our clients with advice based on their proficiency in the market that helps them in creating a compendious database for the clients. Our team offers expert insights to clients to guide them through their business ventures. We put in rigorous efforts to keep our clientele satisfied and focus on fulfilling their demands to make sure that the end-product is what they desire. We excel in diverse fields of the market and with our services extending to competitive analysis, research and development analysis, and demand estimation among others, we can help you invest your funds in the most beneficial areas for research and development. You can rely on us to provide every significant detail you might need in your efforts to make your business flourish.

Contact Us:

John Watson

Head of Business Development

Reports and Data|Web:www.reportsanddata.com

Direct Line:+1-212-710-1370

E-mail:[emailprotected]

Connect with us:Blogs|LinkedIn|Twitter

Go here to read the rest:
Cancer Stem Cell Therapeutics Market Outlooks 2020: Size, Cost Structures, Growth rate and Industry Analysis to 2027 - Eurowire

Biologics Safety Testing Market Research Report by Test Type, by Application – Global Forecast to 2025 – Cumulative Impact of COVID-19 – Yahoo Finance…

Globe Newswire

Dublin, Nov. 05, 2020 (GLOBE NEWSWIRE) -- The "Technology Landscape, Trends and Opportunities in the Global Flexible Packaging Market" report has been added to ResearchAndMarkets.com's offering. This report analyzes technology maturity, degree of disruption, competitive intensity, market potential, and other parameters of various technologies in the flexible packaging market. The technologies in flexible packaging have undergone significant change in recent years, with semi flexible packaging to advance flexible packaging. The rising wave of new technologies such as bio plastics based flexible packaging are creating significant potential in food and beverage, cosmetic and toiletries, and healthcare applications, due to their better protection and recycling benefits.In this market, various technologies, such as plastic film based flexible packaging, aluminium based flexible packaging, paper based flexible packaging, and bio plastic based flexible packaging technologies are used in various applications. Growing demand for bio-based PLA films in various applications and increased shelf life of the products are creating new opportunities for various flexible packaging technologies.The study includes technology readiness, competitive intensity, regulatory compliance, disruption potential, trends, forecasts and strategic implications for the global flexible packaging technology by application, technology, and region.Some of the flexible packaging companies profiled in this report include Bemis Company, Mondi, Huhtamaki Group, Amcor Limited, and BASF.This report answers the following 9 key questions: Q.1 What are some of the most promising and high-growth technology opportunities for the flexible packaging market?Q.2 Which technology will grow at a faster pace and why?Q.3 What are the key factors affecting dynamics of different technologies? What are the drivers and challenges of these technologies in flexible packaging market?Q.4 What are the levels of technology readiness, competitive intensity and regulatory compliance in this technology space?Q.5 What are the business risks and threats to these technologies in flexible packaging market?Q.6 What are the latest developments in flexible packaging technologies? Which companies are leading these developments?Q.7 Which technologies have potential of disruption in this market?Q.8 Who are the major players in this flexible packaging market? What strategic initiatives are being implemented by key players for business growth?Q.9 What are strategic growth opportunities in this flexible packaging technology space? Key Topics Covered: 1. Executive Summary2. Technology Landscape2.1. Technology Background and Evolution2.2. Technology and Application Mapping2.3. Supply Chain3. Technology Readiness3.1. Technology Commercialization and Readiness3.2. Drivers and Challenges in Flexible Packaging Technologies3.3. Competitive Intensity3.4. Regulatory Compliance4. Technology Trends and Forecasts analysis from 2013-20244.1. Flexible Packaging Opportunity4.2. Technology Trends (2013-2018) and Forecasts (2019-2024)4.2.1. Plastic Film based Flexible Packaging4.2.2. Aluminium based Flexible Packaging4.2.3. Paper based Flexible Packaging4.2.4. Bio Plastic based Flexible Packaging4.3. Technology Trends (2013-2018) and Forecasts (2019-2024) by Application Segments4.3.1. Food and Beverage4.3.1.1. Plastic Film based Flexible Packaging4.3.1.2. Aluminium based Flexible Packaging4.3.1.3. Paper based Flexible Packaging4.3.1.4. Bio Plastic based Flexible Packaging4.3.2. Healthcare4.3.3. Cosmetics and Toiletries4.3.4. Other5. Technology Opportunities (2013-2024) by Region5.1. Flexible Packaging Market by Region5.2. North American Flexible Packaging Market5.3. European Flexible Packaging Market5.4. APAC Flexible Packaging Market5.5. ROW Flexible Packaging Market6. Latest Development and Innovation in Flexible Packaging Technologies7. Companies/Ecosystem7.1. Product Portfolio Analysis7.2. Market Share Analysis7.3. Geographical Reach8. Strategic Implications8.1. Implications8.2. Growth Opportunity Analysis8.2.1. Growth Opportunities for the Flexible Packaging Market by Material Technology8.2.2. Growth Opportunities for the Flexible Packaging Market by Application8.2.3. Growth Opportunities for the Flexible Packaging Market by Region8.3. Emerging Trends in the Flexible Packaging Market8.4. Disruption Potential8.5. Strategic Analysis8.5.1. New Product Development8.5.2. Capacity Expansion of the Flexible Packaging Market8.5.3. Mergers, Acquisitions, and Joint Ventures in the Flexible Packaging Market9. Company Profiles of Leading Players9.1. Bemis Company9.2. Mondi9.3. Huhtamaki Group9.4. Amcor Limited9.5. BASF For more information about this report visit https://www.researchandmarkets.com/r/xp7gvs Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research. CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Read the rest here:
Biologics Safety Testing Market Research Report by Test Type, by Application - Global Forecast to 2025 - Cumulative Impact of COVID-19 - Yahoo Finance...

Global Regenerative Medicine Market (2020 to 2025) – Industry Trends, Share, Size, Growth, Opportunity and Forecast – ResearchAndMarkets.com -…

DUBLIN--(BUSINESS WIRE)--The "Regenerative Medicine Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.

The global regenerative medicine market grew at a CAGR of around 16% during 2014-2019. Looking forward, the publisher expects the global regenerative medicine market to continue its strong growth during the next five years.

Regenerative medicine refers to a branch of biomedical sciences aimed at restoring the structure and function of damaged tissues and organs. It involves the utilization of stem cells that are developed in laboratories and further implanted safely into the body for the regeneration of damaged bones, cartilage, blood vessels and organs. Cellular and acellular regenerative medicines are commonly used in various clinical therapeutic procedures, including cell, immunomodulation and tissue engineering therapies. They hold potential for the effective treatment of various chronic diseases, such as Alzheimer's, Parkinson's and cardiovascular disorders (CVDs), osteoporosis and spinal cord injuries.

The increasing prevalence of chronic medical ailments and genetic disorders across the globe is one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is prone to various musculoskeletal, phonological, dermatological and cardiological disorders, is stimulating the market growth. In line with this, widespread adoption of organ transplantation is also contributing to the market growth. Regenerative medicine minimizes the risk of organ rejection by the body post-transplant and enhances the recovery speed of the patient.

Additionally, various technological advancements in cell-based therapies, such as the development of 3D bioprinting techniques and the adoption of artificial intelligence (AI) in the production of regenerative medicines, are acting as other growth-inducing factors. These advancements also aid in conducting efficient dermatological grafting procedures to treat chronic burns, bone defects and wounds on the skin. Other factors, including extensive research and development (R&D) activities in the field of medical sciences, along with improving healthcare infrastructure, are anticipated to drive the market further.

Companies Mentioned

Key Questions Answered in This Report:

Key Topics Covered:

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

4.1 Overview

4.2 Key Industry Trends

5 Global Regenerative Medicine Market

5.1 Market Overview

5.2 Market Performance

5.3 Impact of COVID-19

5.4 Market Forecast

6 Market Breakup by Type

6.1 Stem Cell Therapy

6.1.1 Market Trends

6.1.2 Market Forecast

6.2 Biomaterial

6.2.1 Market Trends

6.2.2 Market Forecast

6.3 Tissue Engineering

6.3.1 Market Trends

6.3.2 Market Forecast

6.4 Others

6.4.1 Market Trends

6.4.2 Market Forecast

7 Market Breakup by Application

7.1 Bone Graft Substitutes

7.1.1 Market Trends

7.1.2 Market Forecast

7.2 Osteoarticular Diseases

7.2.1 Market Trends

7.2.2 Market Forecast

7.3 Dermatology

7.3.1 Market Trends

7.3.2 Market Forecast

7.4 Cardiovascular

7.4.1 Market Trends

7.4.2 Market Forecast

7.5 Central Nervous System

7.5.1 Market Trends

7.5.2 Market Forecast

7.6 Others

7.6.1 Market Trends

7.6.2 Market Forecast

8 Market Breakup by End User

8.1 Hospitals

8.1.1 Market Trends

8.1.2 Market Forecast

8.2 Specialty Clinics

8.2.1 Market Trends

8.2.2 Market Forecast

8.3 Others

8.3.1 Market Trends

8.3.2 Market Forecast

9 Market Breakup by Region

9.1 North America

9.2 Asia Pacific

9.3 Europe

9.4 Latin America

9.5 Middle East and Africa

10 SWOT Analysis

11 Value Chain Analysis

12 Porters Five Forces Analysis

13 Price Analysis

14 Competitive Landscape

14.1 Market Structure

14.2 Key Players

14.3 Profiles of Key Players

For more information about this report visit https://www.researchandmarkets.com/r/erd0e3

Read the original:
Global Regenerative Medicine Market (2020 to 2025) - Industry Trends, Share, Size, Growth, Opportunity and Forecast - ResearchAndMarkets.com -...

Stem Cell Media Market Projected to Witness Vigorous Expansion by 2027 – The Think Curiouser

Bigmarketresearch, one of the worlds prominent market research firms has released a new report on GlobalStem Cell Media Market.The report contains crucial insights on the market which will support the clients to make the right business decisions. This research will help both existing and new aspirants for Stem Cell Media market to figure out and study market needs, market size, and competition. The report talks about the supply and demand situation, the competitive scenario, and the challenges for market growth, market opportunities, and the threats faced by Top key players.

The global Stem Cell Media market is expected to witness a promising growth in the next few years. The rising level of competition among the leading players and the rising focus on the development of new products are likely to offer promising growth opportunities throughout the forecast period. The research study on the global Stem Cell Media market offers a detailed overview, highlighting the key aspects that are expected to enhance the growth of the market in the near future. The key segmentation and the competitive landscape of the market have also been mentioned at length in the research study.

Get Free Sample PDF Copy of Stem Cell Media with Figures, Graphs and Tocs:https://www.bigmarketresearch.com/request-sample/3432325?utm_source=PRL&utm_medium=Wasim

The report also includes the impact of ongoing global crisis i.e.COVID-19on the Stem Cell Media market and what the future holds for it. The published report is designed using a vigorous and thorough research methodology andbigmarketresearchis also known for its data accuracy and granular market reports.

This report studies the Stem Cell Media market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Stem Cell Media market by product type and applications/end industries. These details further contain a basic summary of the company, merchant profile, and the product range of the company in question. The report analyzes data regarding the proceeds accrued, product sales, gross margins, price patterns, and news updates relating to the company.

Market drivers, restraints, challenges, and opportunities have been discussed in detail.Market players have been discussed and profiles of leading players including: Thermo Fisher STEMCELL Technologies Merck Millipore Lonza GE Healthcare Miltenyi Biotec Corning CellGenix Takara PromoCell

The key product type,the Stem Cell Media market is primarily split into Pluripotent Stem Cell Culture Hematopoietic Stem Cell Culture Mesenchymal Stem Cell Culture

Based on type, the global market is segmented into the following sub-markets with annual revenue for 2015-2025 (historical and forecast) included in each section.

The end users/applications listed in the report are: Scientific Research Industrial Production

Based on application, the global market is segmented into the following sub-markets with annual revenue for 2019-2025 (historical and forecast) included in each section.

Get the Full Research Report Copy of Stem Cell Media With 10% Off by using Coupon Code [ORG123WA]:https://www.bigmarketresearch.com/request-for-discount/3432325?utm_source=PRL&utm_medium=Wasim

This report estimates the market size in terms of volume and value. This has been broken down into component regions and further into countries within those regions. This report covers North America, Europe, Middle East & Africa and Asia-Pacific and South America.

The report helps to identify the main Stem Cell Media market players. It assists in analyzing Stem Cell Media market competitive environment, including company overview, company total revenue, market opportunities, value, production sites and facilities, SWOT analysis, product details. The study also reveals the sales, revenue and market share for each market player included in this report for the period of 2015-2020. It also helps to ascertain the growth drivers and future prospects for the forecast timeline.

Conclusively, this report is a one stop reference point for the industrial stakeholders to get Stem Cell Media market forecast of till 2025. This report helps to know the estimated market size, market status, future development, growth opportunity, challenges, and growth drivers of by analyzing the historical overall data of the considered market segments.

You May Also Like Our Other Trending Reports:

Read More:https://www.bigmarketresearch.com/report/3565591/global-ferrite-magnets-sale-insights-market?utm_source=PRL&utm_medium=Wasim

About Us:

Big Market Research has a range of research reports from various domains across the world. Our database of reports of various market categories and sub-categories would help to find the exact report you may be looking for.

Contact us: Mr. Abhishek Paliwal 5933 NE Win Sivers Drive, #205, Portland, OR 97220 United States Direct: +1-971-202-1575 Toll Free: +1-800-910-6452 E-mail:[emailprotected]

See original here:
Stem Cell Media Market Projected to Witness Vigorous Expansion by 2027 - The Think Curiouser

Cell Isolation Market Research and Analysis by Expert: import/export details, Cost Structures and statistics till 2027 – KYT24

Cell Isolation Market Report

The research study on the Global Cell Isolation Market is a thorough investigation of the value and supply chain of the market and offers all-inclusive data about the industry. The report also covers insightful information about pricing, cost, value, capacity, gross revenue, and profit margins with reference to historical analysis and forecast estimation. The report also strives to identify demands and trends in different sectors of the Cell Isolation market in major geographies of the world.

The Cell Isolation market has witnessed dynamic changes in trends and demands owing to the ongoing COVID-19 pandemic. The report provides a detailed outlook on how the pandemic has affected the key segments of the Cell Isolation industry. The report includes an in-depth impact analysis of the COVID-19 pandemic on the overall Cell Isolation industry and covers a futuristic impact scenario.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/2237

The report studies the market dynamics to identify and scrutinize the strategic initiatives and tactics undertaken by the industry players in order to gain a robust footing in the market and to achieve a substantial global position. It provides exhaustive analysis and imparts insightful data to help the readers understand the Cell Isolation industry in detail and gain a competitive advantage over other players. The report also provides strategic recommendations to new and emerging players to help them formulate better entry and investment strategies.

The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies. The key players studied in the report include:

Thermo Fisher Scientific, Beckman Coulter, Becton, Dickinson and Company, GE Healthcare, Merck KgaA, Miltenyi Biotec, pluriSelect, STEMCELL Technologies Inc., Terumo BCT and Bio-Rad Laboratories Inc. who are investing a lot in research and development to bring in innovations to carve a niche market for themselves and get an advantage over their competitors.

The report offers a comprehensive analysis of the Cell Isolation market inclusive of product portfolio, categories, applications, and a comprehensive analysis of the value chain structure. The study investigates several factors influencing the growth of the market and provides a competitive advantage to the readers.

The Cell Isolation market report is an investigative study that provides insights into opportunities, limitations, and barriers encountered by the companies that influence or hinder the growth of the industry. Overall the report provides valuable information and an overview of the market scenario to gain a better understanding of the market.

Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/2237

Product (Revenue in USD Billion, 2018 2026)

Cell Type (Revenue in USD Billion, 2018 2026)

Technique (Revenue in USD Billion, 2018 2026)

Application (Revenue in USD Billion, 2018 2026)

End Use (Revenue in USD Billion, 2018 2026)

The report covers an extensive regional analysis and market estimation in each region and covers key geographical regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa.

To read more about the report, visit @ https://www.reportsanddata.com/report-detail/cell-isolation-market

Key Point Summary of the Report:

Thank you for reading our report. For further queries, please connect with us to know more about the report and its customization. Our team will ensure the report is customized accurately to meet your requirements.

Take a look at other reports from Reports and Data on PR Newswire:

Spine Biologics Market: Spine Biologics Market to Reach USD 2,629.6 Million By 2027 | CAGR: 3.9%

Isobutanol Market: Isobutanol Market to Reach USD 1555.8 Million By 2027 | CAGR: 6.4%

Hematology Analyzers and Reagents Market: Hematology Analyzers and Reagents Market to Reach USD 12.10 Billion By 2027

Isobutanol Market: Isobutanol Market to Reach USD 1555.8 Million By 2027 | CAGR: 6.4%

About Us:

Our in-house experts assist our clients with advice based on their proficiency in the market that helps them in creating a compendious database for the clients. Our team offers expert insights to clients to guide them through their business ventures. We put in rigorous efforts to keep our clientele satisfied and focus on fulfilling their demands to make sure that the end-product is what they desire. We excel in diverse fields of the market and with our services extending to competitive analysis, research and development analysis, and demand estimation among others, we can help you invest your funds in the most beneficial areas for research and development. You can rely on us to provide every significant detail you might need in your efforts to make your business flourish.

Contact Us:

John Watson

Head of Business Development

Reports and Data|Web:www.reportsanddata.com

Direct Line:+1-212-710-1370

E-mail:[emailprotected]

Connect with us:Blogs|LinkedIn|Twitter

See original here:
Cell Isolation Market Research and Analysis by Expert: import/export details, Cost Structures and statistics till 2027 - KYT24

MorphoSys to Present Data on Tafasitamab at the ASH Virtual Annual Meeting and Exposition – PharmiWeb.com

DGAP-News: MorphoSys AG / Key word(s): Miscellaneous 04.11.2020 / 23:15 The issuer is solely responsible for the content of this announcement.

Media Release Planegg/Munich, Germany, November 4, 2020

MorphoSys to Present Data on Tafasitamab at the ASH Virtual Annual Meeting and Exposition

MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) today announced that multiple abstracts regarding the company's proprietary key asset tafasitamab have been accepted for poster presentations and online publication at the upcoming 62nd ASH Virtual Annual Meeting and Exposition from December 05-December 08, 2020. Tafasitamab is MorphoSys' CD19-directed antibody which was recently approved by the U.S. Food and Drug Administration in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT). This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

"We are pleased that pre-clinical data from MorphoSys' research department as well as clinical data from trials investigating our proprietary antibody tafasitamab were selected for presentation at the upcoming virtual ASH Meeting and Exposition," commented Dr. Malte Peters, Chief Research and Development Officer at MorphoSys. "Our seven accepted abstracts provide insights into our scientific and clinical activities to evaluate the efficacy and safety of tafasitamab in B-cell lymphoma. They highlight our commitment to unlock the full potential of tafasitamab and continue to broaden the development of our key asset as a therapeutic option for patients with high unmet medical needs."

MorphoSys will host a virtual booth for registered ASH Virtual Annual Meeting and Exposition attendees.

Abstracts accepted for presentation at ASH Virtual Annual Meeting and Exposition include:

E-Poster presentations:

LONG-TERM SUBGROUP ANALYSES FROM L-MIND, A PHASE II STUDY OF TAFASITAMAB (MOR208) COMBINED WITH LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA Abstract number: 140314 Publication number: 3021 Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)-Results from Prospective Clinical Trials Poster presentation: Monday, December 7, 2020

A PHASE IB, OPEN-LABEL, RANDOMIZED STUDY TO ASSESS SAFETY AND PRELIMINARY EFFICACY OF TAFASITAMAB (MOR208) OR TAFASITAMAB + LENALIDOMIDE IN ADDITION TO R-CHOP IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA: ANALYSIS OF THE SAFETY RUN-IN PHASE Abstract number: 139788 Publication number: 3028 Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)-Results from Prospective Clinical Trials Poster presentation: Monday, December 7, 2020

THE COMBINATION OF TAFASITAMAB AND RITUXIMAB INCREASES CYTOTOXICITY AGAINST LYMPHOMA CELLS IN VITRO Abstract number: 140381 Publication number: 2095 Session: 625. Lymphoma: Pre-Clinical-Chemotherapy and Biologic Agents Poster presentation date: Sunday, December 6, 2020

BLOCKADE OF THE CD47/SIRP CHECKPOINT POTENTIATES THE ANTI-TUMOR EFFICACY OF TAFASITAMAB Abstract number: 139582 Publication number: 3008 Session: 625. Lymphoma: Pre-Clinical-Chemotherapy and Biologic Agents Poster presentation date: Monday, December 7, 2020

Abstracts published online:

EFFICACY OF TAFASITAMAB (MOR208) COMBINED WITH LENALIDOMIDE IN PATIENTS WITH HIGH-RISK RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN THE L-MIND STUDY Abstract number: 140294 Publication number: 3918

ESTIMATION OF LONG-TERM SURVIVAL WITH TAFASITAMAB + LENALIDOMIDE IN RELAPSED/ REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA Abstract number: 140398 Publication number: 3928

MAINTAINED CD19 EXPRESSION IN DLBCL PATIENTS AFTER TAFASITAMAB THERAPY IN THE L-MIND STUDY WITHOUT EVIDENCE OF EXON SKIPPING OR SOMATIC MUTATIONS Abstract number: 139149 Publication number: 3723

The abstracts will also be available online in a supplemental issue of Blood. Please refer to the ASH Virtual Annual Meeting and Exposition online program (https://www.hematology.org) for full session details and data presentation listings.

About Tafasitamab Tafasitamab is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. Tafasitamab incorporates an XmAb(R) engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).

Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT). This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

In January 2020, MorphoSys and Incyte entered into a collaboration and licensing agreement to further develop and commercialize tafasitamab globally. Monjuvi(R) is being co-commercialized by Incyte and MorphoSys in the United States. Incyte has exclusive commercialization rights outside the United States.

A marketing authorization application (MAA) seeking the approval of tafasitamab in combination with lenalidomide in the EU has been validated by the European Medicines Agency (EMA) and is currently under review for the treatment of adult patients with relapsed or refractory DLBCL, including DLBCL arising from low grade lymphoma, who are not candidates for ASCT.

Tafasitamab is being clinically investigated as a therapeutic option in B-cell malignancies in a number of ongoing combination trials.

Monjuvi(R) is a registered trademark of MorphoSys AG. XmAb(R) is a registered trademark of Xencor, Inc.

Important Safety Information What are the possible side effects of MONJUVI? MONJUVI may cause serious side effects, including:

- Infusion reactions. Your healthcare provider will monitor you for infusion reactions during your infusion of MONJUVI. Tell your healthcare provider right away if you get chills, flushing, headache, or shortness of breath during an infusion of MONJUVI.

- Low blood cell counts (platelets, red blood cells, and white blood cells). Low blood cell counts are common with MONJUVI, but can also be serious or severe. Your healthcare provider will monitor your blood counts during treatment with MONJUVI. Tell your healthcare provider right away if you get a fever of 100.4 F (38 C) or above, or any bruising or bleeding.

- Infections. Serious infections, including infections that can cause death, have happened in people during treatments with MONJUVI and after the last dose. Tell your healthcare provider right away if you get a fever of 100.4 F (38 C) or above, or develop any signs and symptoms of an infection.

The most common side effects of MONJUVI include:

- Feeling tired or weak

- Diarrhea

- Cough

- Fever

- Swelling of lower legs or hands

- Respiratory tract infection

- Decreased appetite

These are not all the possible side effects of MONJUVI. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before you receive MONJUVI, tell your healthcare provider about all your medical conditions, including if you:

- Have an active infection or have had one recently.

- Are pregnant or plan to become pregnant. MONJUVI may harm your unborn baby. You should not become pregnant during treatment with MONJUVI. Do not receive treatment with MONJUVI in combination with lenalidomide if you are pregnant because lenalidomide can cause birth defects and death of your unborn baby.

- You should use an effective method of birth control (contraception) during treatment and for at least 3 months after your final dose of MONJUVI.

- Tell your healthcare provider right away if you become pregnant or think that you may be pregnant during treatment with MONJUVI.

- Are breastfeeding or plan to breastfeed. It is not known if MONJUVI passes into your breastmilk. Do not breastfeed during treatment for at least 3 months after your last dose of MONJUVI.

You should also read the lenalidomide Medication Guide for important information about pregnancy, contraception, and blood and sperm donation.

Tell your healthcare provider about all the medications you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Please see the full Prescribing Information for Monjuvi, including Patient Information, for additional Important Safety Information.

About MorphoSys MorphoSys (FSE & NASDAQ: MOR) is a commercial-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases. The focus is on cancer. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 27 are currently in clinical development. In 2017, Tremfya(R), developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc., for the treatment of plaque psoriasis, became the first drug based on MorphoSys' antibody technology to receive regulatory approval. In July 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval of MorphoSys' proprietary product Monjuvi(R) (tafasitamab-cxix) in combination with lenalidomide in patients with a certain type of lymphoma.

Headquartered near Munich, Germany, the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US Inc., has ~500 employees. More information at http://www.morphosys.com or http://www.morphosys-us.com.

Monjuvi(R) is a registered trademark of MorphoSys AG. Tremfya(R) is a registered trademark of Janssen Biotech, Inc.

MorphoSys Forward-Looking Statements This communication contains certain forward-looking statements concerning the MorphoSys group of companies, including the expectations regarding Monjuvi's ability to treat patients with relapsed or refractory diffuse large B-cell lymphoma, the further clinical development of tafasitamab-cxix, including ongoing confirmatory trials, additional interactions with regulatory authorities and expectations regarding future regulatory filings and possible additional approvals for tafasitamab-cxix as well as the commercial performance of Monjuvi. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "would," "could," "potential," "possible," "hope" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are MorphoSys' expectations regarding risks and uncertainties related to the impact of the COVID-19 pandemic to MorphoSys' business, operations, strategy, goals and anticipated milestones, including its ongoing and planned research activities, ability to conduct ongoing and planned clinical trials, clinical supply of current or future drug candidates, commercial supply of current or future approved products, and launching, marketing and selling current or future approved products, the global collaboration and license agreement for tafasitamab, the further clinical development of tafasitamab, including ongoing confirmatory trials, and MorphoSys' ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials, additional interactions with regulatory authorities and expectations regarding future regulatory filings and possible additional approvals for tafasitamab-cxix as well as the commercial performance of Monjuvi, MorphoSys' reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors included in MorphoSys' Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.

For more information, please contact:

04.11.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at http://www.dgap.de

Here is the original post:
MorphoSys to Present Data on Tafasitamab at the ASH Virtual Annual Meeting and Exposition - PharmiWeb.com

The Many Model Systems of COVID-19 – The Scientist

Earlier this year, as transmission of SARS-CoV-2, the virus behind the COVID-19 pandemic, started to pick up speed, researchers around the world hurried to find model systems that could provide insight into disease spread, host immune responses, and possible treatments.

When the pandemic first started, nobody really knew what was going to be the best model, says Amanda Martinot, a veterinary pathologist at Tufts Cummings School of Veterinary Medicine.

The most widely available candidates were mice, which are easily housed and so well-researched that there are tons of tools available for studying nearly every aspect of their biology. But as researchers suspected, based on previous incompatibility of mice and other coronaviruses, the animals present challenges when it comes to studying SARS-CoV-2. The virus uses a human receptor called ACE2 to get into cells, but mouse ACE2 is different enough that the virus doesnt readily bind it.

Scientists have overcome the issue using two separate strategies: generating transgenic animals that express the human receptor and modifying the SARS-CoV-2 virus to make it better able to bind mouse ACE2.

Even with the success of those approaches, investigators have also been on the lookout for other options. Ferrets, for instance, are useful for studying viral transmission and viral replication in the upper respiratory tract and have been used by several groups for SARS-CoV-2 experiments. Some researchers have also turned to hamsters, which have been used in the past to study other viruses, including the coronaviruses responsible for severe acute respiratory syndrome and Middle East respiratory syndrome.

Hamsters are known in virology for their permissiveness to all kinds of viral infection really, and, as a rule of thumb, I would say if something doesnt work in a mouse, you may as well try a hamster, says Jakob Trimpert, a postdoc at the Free University of Berlin. And if youre lucky, it works there. Along with collaborators, hes been using several species of hamsters to study SARS-CoV-2 infections and potential therapeutics.

The hamster ACE2 receptor is compatible with SARS-CoV-2, and the animals develop clear clinical indicators of disease, he explains. For instance, Syrian hamsters(Mesocricetus auratus), one of the hamster species most commonly used in virus research worldwide, get mild SARS-CoV-2 infections, but their main symptomweight lossis reproducible and possible to measure. These animals also have severe pneumonia that is detectable via lung pathology. Trimpert and his colleagues used both transcriptomics and proteomics to evaluate the animals immune responses to SARS-CoV-2 in a study they published on July 20.

Many alveolar air spaces (white) are collapsed during a SARS-CoV-2 lung infection in a Syrian hamster (right). They are not collapsed in an uninfected hamsters lung (left).

Amanda martinot, tufts cummings school of veterinary medicine

Hamsters have been the best model so far for showing us any clinical disease, says Martinot. They develop weight loss, and they develop a fulminant pneumonia where its affecting sometimes over fifty percent of their lung, she adds. They also will recover if given time, but the pathology we feel is more representative of what you might see in humans. Martinot, Dan Barouch, who directs the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center, and other collaborators recently published a study showing that a SARS-CoV-2 vaccine protected against weight loss and pneumonia in Syrian hamsters.

This species, also known as the golden Syrian hamster, has some drawbacks, too, Trimpert says. Theyre big, for one, weighing in at 150160 grams fully grown, in contrast to adult mice, which tip the scales at about 3035 grams. Syrian hamsters are also aggressive toward each other and sometimes the people taking care of them. Their size and aggression mean that they often have to be housed alone in larger cages, which makes them more expensive to keep.

The biggest issues, according to Trimpert, are the poor quality of the sequenced genomemany genes are just missingand the lack of molecular tools that work in hamsters. To circumvent these problems, Trimpert and his colleagues are resequencing and annotating the Syrian hamster genome.

Because the weight loss in Syrian hamsterstheir only easily observable clinical symptomis quite mild, its also a drawback, particularly when testing therapies or vaccines, Trimpert tells The Scientist. If you need thirty hamsters in order to get statistical significance . . . that is a huge practical problem.

The researchers are skirting this issue by beginning work with another species, Roborovski dwarf hamsters (Phodopus roborovskii), which are smaller than mice and less aggressive than Syrian hamsters. The dwarf hamsters also get much sicker than their larger relatives following SARS-CoV-2 infection, developing massive blood clots in the lungs, which are often present in severe cases of COVID-19 in people as well. Most of these hamsters eventually die of the complications of the infection, which, according to Trimpert, indicates that they might be a good model of severe disease in humans.

A human intestinal organoid (with nuclei labeled in blue and cell shape outlined in green) infected with SARS-CoV-2 (labeled in red)

Joep Beumer

Getting a better picture of what is happening in people is a common goal. Eric Song, an MD/PhD student in Akiko Iwasakis lab at Yale School of Medicine, wanted to determine what effect SARS-CoV-2 was having on the brain. He and his colleagues used a humanized mouse model, in which a promoter drives the expression of human ACE2 in epithelial cells, in a study released as a preprint earlier this year. They found that SARS-CoV-2 could infect the central nervous system in the mice, but it still wasnt clear whether those findings translated to human patients.

To probe that question, the researchers turned to brain organoidscultured, miniature organs that resemble the developing brain and contain neuronal and glial cell types derived from human induced pluripotent stem cells (iPSCs). Not only did SARS-CoV-2 infect the organoids, infection also appeared to cause cell death, a finding corroborated by another study in brain organoids published by separate group September 23. Song and his colleagues also found antibodies against SARS-CoV-2 in the cerebrospinal fluid of people with COVID-19 and evidence of SARS-CoV-2 infection in the post-mortem brains of COVID-19 patients.

The team used three complementary methods to account for the limitations of each, Song tells The Scientist.There is room for all the different models that are in play, he adds. With human samples, you can only take really a snapshot of the sickest patients because thats the only time you will be getting a post-mortem sample, but combined with the mouse and the organoid model, youre able to study [the] kinetics and the dynamic process of viral invasion. Things like organoids really help us access tissues that we would not otherwise have access to.

Immunologist and developmental biologist Hans Clevers of Utrecht University in the Netherlands and colleagues are leveraging that access with gut organoids. Rather than deriving the organoids from iPSCs, though, they use multipotent stem cells taken from any adult epithelial tissue. In some ways the strategy is more limited: gut epithelial cells can only make mini guts, for instance, in contrast to iPSC-derived organoids, which can become lots of different tissues. On the other hand, they grow forever, Clevers says. iPSC-based organoids, you make them and then you have to use them for an experiment because they stop growing the moment you start specifying them.

His group published a study on July 3 investigating whether or not SARS-CoV-2 can target the gut, a hypothesis based on the expression of ACE2 in the intestinal lining and the gastrointestinal symptoms that many COVID-19 patients experience. Their work in human small intestinal organoids confirmed that the virus does enter the cells of the intestinal lining, replicate, and cause changes in gene expression.

Now, Clevers and his colleagues are using organoids to test possible COVID-19 therapeutics. Chloroquine is an example of a drug that looked promising for blocking SARS-CoV-2 infection when researchers tried it in conventional cell culturein that case, cells derived from African green monkey kidneys and grown in one layer on a dish, he says. But, as theyve shown in a new study thats been submitted for peer review, in the gut organoid model chloroquine is ineffective against SARS-CoV-2, just as it is in patients. According to Clevers, this latest finding indicates that an extra screening step in organoids following the identification of a promising drug in a traditional cell culture system could provide another layer of information before moving into preclinical animal models or the clinic.

Cell lines are cheap, they grow fast, and most robotic strategies for screening have been designed for cells growing in two dimensions, Clevers says. There are multiple efforts now around the world to come up with the machines to do similar high throughput screens with 3D. With the organoids, its a little bit more complex to analyze because theyre not flat, he explains, but the type of organoids they generate in his lab grow quickly. He predicts that organoids will come to be used more widely because their physiology recapitulates that of humans so well, but that theyll never replace animals.

Along with hamsters, nonhuman primates are one of the main models that researchers studying COVID-19 therapeutics use. SARS-CoV-2 readily infects primates, such as macaques, due to the compatibility of their ACE2 receptor, but they do not show disease symptoms, says Martinot. The nonhuman primate experience of COVID-19 seems to be most similar to the mildly symptomatic cases of most people who are infected, she adds. They develop regions of pathology in their lungs that are detectable with a microscope, but its not enough to make them sick, and observing that kind of disease in a person is unlikely because these animals are euthanized early in infection to allow researchers to track any changes.

It would be nice to have a primate model of severe disease, says Barouch. Nobody has been able to develop one so far, but models are always in development.

And symptom presentation isnt everything. These animals are harder to access and harder to house than rodents, but they are a wonderful model for vaccine research and for evaluating . . . the adaptive immune response to COVID-19, Martinot says, at least in part because there are so many existing tools researchers can leverage. Reagents that are available for evaluating the immune response [in people] work in monkeys, and so we can very carefully monitor the nonhuman primate for the development of antibodies, cytokine responses, and T-cell responses, she adds.

You always want to pick your best model for your specific question, Martinot tells The Scientist. But depending on what kind of question youre asking, or what kind of drug youre testing, you really have to choose the model that best fits your ability to answer those questions in a very accurate and reproducible way.

The World Health Organizations Research & Development Blueprint Team has been working on this since February. The team reviews progress and coordinates efforts on animal models of COVID-19 with the primary goal of advancing the development of COVID-19 therapeutics and vaccines. On September 23, some group members and a handful of other researchers published a review detailing the work thats been done to model SARS-CoV-2 infections in animalsparticularly, mice, hamsters, ferrets, and nonhuman primatesand highlighting how findings in animals correspond to disease progression in people.

The development and use of these models is not a linear process, and theyre under constant revision, says Barouch, who is part of the WHO working group. When there is human data, then that allows back validation or refinement of the model . . . so there has to be a continuous feedback from models to clinical trials and back.

In things that are so new, like SARS-CoV-2, it may well be that there is more than one useful animal model, Trimpert says. We should be open and flexible, especially in emergency situations like this.

Read more:
The Many Model Systems of COVID-19 - The Scientist

Soybean Trypsin Inhibitor Market Brief Analysis and Application, Growth by 2026 | Biological Industries, Thermo Fisher Scientific, Sigma-Aldrich…

LOS ANGELES, United States: The report is an all-inclusive research study of the global Soybean Trypsin Inhibitor market taking into account the growth factors, recent trends, developments, opportunities, and competitive landscape. The market analysts and researchers have done extensive analysis of the global Soybean Trypsin Inhibitor market with the help of research methodologies such as PESTLE and Porters Five Forces analysis. They have provided accurate and reliable market data and useful recommendations with an aim to help the players gain an insight into the overall present and future market scenario. The Soybean Trypsin Inhibitor report comprises in-depth study of the potential segments including product type, application, and end user and their contribution to the overall market size.

Get PDF Sample Copy of Report: (Including TOC, List of Tables & Figures, Chart) https://www.qyresearch.com/sample-form/form/1611144/global-soybean-trypsin-inhibitor-market

In addition, market revenues based on region and country are provided in the Soybean Trypsin Inhibitor report. The authors of the report have also shed light on the common business tactics adopted by players. The leading players of the global Soybean Trypsin Inhibitor market and their complete profiles are included in the report. Besides that, investment opportunities, recommendations, and trends that are trending at present in the global Soybean Trypsin Inhibitor market are mapped by the report. With the help of this report, the key players of the global Soybean Trypsin Inhibitor market will be able to make sound decisions and plan their strategies accordingly to stay ahead of the curve.

Competitive landscape is a critical aspect every key player needs to be familiar with. The report throws light on the competitive scenario of the global Soybean Trypsin Inhibitor market to know the competition at both the domestic and global levels. Market experts have also offered the outline of every leading player of the global Soybean Trypsin Inhibitor market, considering the key aspects such as areas of operation, production, and product portfolio. Additionally, companies in the report are studied based on the key factors such as company size, market share, market growth, revenue, production volume, and profits.

Key Players Mentioned in the Global Soybean Trypsin Inhibitor Market Research Report: Biological Industries, Thermo Fisher Scientific, Sigma-Aldrich (Merck), Oxford Biomedical Research (OBR), STEMCELL, Cayman Chemical, Worthington Biochemical, Geno Technology, Abcam

Types: Purity Above 90% Purity Above 95% Other

Applications: Scientific Research Industrial Production Other

The Soybean Trypsin Inhibitor Market report has been segregated based on distinct categories, such as product type, application, end user, and region. Each and every segment is evaluated on the basis of CAGR, share, and growth potential. In the regional analysis, the report highlights the prospective region, which is estimated to generate opportunities in the global Soybean Trypsin Inhibitor market in the forthcoming years. This segmental analysis will surely turn out to be a useful tool for the readers, stakeholders, and market participants to get a complete picture of the global Soybean Trypsin Inhibitor market and its potential to grow in the years to come.

Key questions answered in the report:

Request for customization in Report: https://www.qyresearch.com/customize-request/form/1611144/global-soybean-trypsin-inhibitor-market

Table of Contents:

1 Soybean Trypsin Inhibitor Market Overview 1.1 Product Overview and Scope of Soybean Trypsin Inhibitor 1.2 Soybean Trypsin Inhibitor Segment by Type 1.2.1 Global Soybean Trypsin Inhibitor Sales Growth Rate Comparison by Type (2021-2026) 1.2.2 Purity Above 90% 1.2.3 Purity Above 95% 1.2.4 Other 1.3 Soybean Trypsin Inhibitor Segment by Application 1.3.1 Soybean Trypsin Inhibitor Sales Comparison by Application: 2020 VS 2026 1.3.2 Scientific Research 1.3.3 Industrial Production 1.3.4 Other 1.4 Global Soybean Trypsin Inhibitor Market Size Estimates and Forecasts 1.4.1 Global Soybean Trypsin Inhibitor Revenue 2015-2026 1.4.2 Global Soybean Trypsin Inhibitor Sales 2015-2026 1.4.3 Soybean Trypsin Inhibitor Market Size by Region: 2020 Versus 2026 1.5 Soybean Trypsin Inhibitor Industry 1.6 Soybean Trypsin Inhibitor Market Trends

2 Global Soybean Trypsin Inhibitor Market Competition by Manufacturers 2.1 Global Soybean Trypsin Inhibitor Sales Market Share by Manufacturers (2015-2020) 2.2 Global Soybean Trypsin Inhibitor Revenue Share by Manufacturers (2015-2020) 2.3 Global Soybean Trypsin Inhibitor Average Price by Manufacturers (2015-2020) 2.4 Manufacturers Soybean Trypsin Inhibitor Manufacturing Sites, Area Served, Product Type 2.5 Soybean Trypsin Inhibitor Market Competitive Situation and Trends 2.5.1 Soybean Trypsin Inhibitor Market Concentration Rate 2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue 2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans 2.7 Primary Interviews with Key Soybean Trypsin Inhibitor Players (Opinion Leaders)

3 Soybean Trypsin Inhibitor Retrospective Market Scenario by Region 3.1 Global Soybean Trypsin Inhibitor Retrospective Market Scenario in Sales by Region: 2015-2020 3.2 Global Soybean Trypsin Inhibitor Retrospective Market Scenario in Revenue by Region: 2015-2020 3.3 North America Soybean Trypsin Inhibitor Market Facts & Figures by Country 3.3.1 North America Soybean Trypsin Inhibitor Sales by Country 3.3.2 North America Soybean Trypsin Inhibitor Sales by Country 3.3.3 U.S. 3.3.4 Canada 3.4 Europe Soybean Trypsin Inhibitor Market Facts & Figures by Country 3.4.1 Europe Soybean Trypsin Inhibitor Sales by Country 3.4.2 Europe Soybean Trypsin Inhibitor Sales by Country 3.4.3 Germany 3.4.4 France 3.4.5 U.K. 3.4.6 Italy 3.4.7 Russia 3.5 Asia Pacific Soybean Trypsin Inhibitor Market Facts & Figures by Region 3.5.1 Asia Pacific Soybean Trypsin Inhibitor Sales by Region 3.5.2 Asia Pacific Soybean Trypsin Inhibitor Sales by Region 3.5.3 China 3.5.4 Japan 3.5.5 South Korea 3.5.6 India 3.5.7 Australia 3.5.8 Taiwan 3.5.9 Indonesia 3.5.10 Thailand 3.5.11 Malaysia 3.5.12 Philippines 3.5.13 Vietnam 3.6 Latin America Soybean Trypsin Inhibitor Market Facts & Figures by Country 3.6.1 Latin America Soybean Trypsin Inhibitor Sales by Country 3.6.2 Latin America Soybean Trypsin Inhibitor Sales by Country 3.6.3 Mexico 3.6.3 Brazil 3.6.3 Argentina 3.7 Middle East and Africa Soybean Trypsin Inhibitor Market Facts & Figures by Country 3.7.1 Middle East and Africa Soybean Trypsin Inhibitor Sales by Country 3.7.2 Middle East and Africa Soybean Trypsin Inhibitor Sales by Country 3.7.3 Turkey 3.7.4 Saudi Arabia 3.7.5 U.A.E 4 Global Soybean Trypsin Inhibitor Historic Market Analysis by Type 4.1 Global Soybean Trypsin Inhibitor Sales Market Share by Type (2015-2020) 4.2 Global Soybean Trypsin Inhibitor Revenue Market Share by Type (2015-2020) 4.3 Global Soybean Trypsin Inhibitor Price Market Share by Type (2015-2020) 4.4 Global Soybean Trypsin Inhibitor Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Global Soybean Trypsin Inhibitor Historic Market Analysis by Application 5.1 Global Soybean Trypsin Inhibitor Sales Market Share by Application (2015-2020) 5.2 Global Soybean Trypsin Inhibitor Revenue Market Share by Application (2015-2020) 5.3 Global Soybean Trypsin Inhibitor Price by Application (2015-2020)

6 Company Profiles and Key Figures in Soybean Trypsin Inhibitor Business 6.1 Biological Industries 6.1.1 Corporation Information 6.1.2 Biological Industries Description, Business Overview and Total Revenue 6.1.3 Biological Industries Soybean Trypsin Inhibitor Sales, Revenue and Gross Margin (2015-2020) 6.1.4 Biological Industries Products Offered 6.1.5 Biological Industries Recent Development 6.2 Thermo Fisher Scientific 6.2.1 Thermo Fisher Scientific Corporation Information 6.2.2 Thermo Fisher Scientific Description, Business Overview and Total Revenue 6.2.3 Thermo Fisher Scientific Soybean Trypsin Inhibitor Sales, Revenue and Gross Margin (2015-2020) 6.2.4 Thermo Fisher Scientific Products Offered 6.2.5 Thermo Fisher Scientific Recent Development 6.3 Sigma-Aldrich (Merck) 6.3.1 Sigma-Aldrich (Merck) Corporation Information 6.3.2 Sigma-Aldrich (Merck) Description, Business Overview and Total Revenue 6.3.3 Sigma-Aldrich (Merck) Soybean Trypsin Inhibitor Sales, Revenue and Gross Margin (2015-2020) 6.3.4 Sigma-Aldrich (Merck) Products Offered 6.3.5 Sigma-Aldrich (Merck) Recent Development 6.4 Oxford Biomedical Research (OBR) 6.4.1 Oxford Biomedical Research (OBR) Corporation Information 6.4.2 Oxford Biomedical Research (OBR) Description, Business Overview and Total Revenue 6.4.3 Oxford Biomedical Research (OBR) Soybean Trypsin Inhibitor Sales, Revenue and Gross Margin (2015-2020) 6.4.4 Oxford Biomedical Research (OBR) Products Offered 6.4.5 Oxford Biomedical Research (OBR) Recent Development 6.5 STEMCELL 6.5.1 STEMCELL Corporation Information 6.5.2 STEMCELL Description, Business Overview and Total Revenue 6.5.3 STEMCELL Soybean Trypsin Inhibitor Sales, Revenue and Gross Margin (2015-2020) 6.5.4 STEMCELL Products Offered 6.5.5 STEMCELL Recent Development 6.6 Cayman Chemical 6.6.1 Cayman Chemical Corporation Information 6.6.2 Cayman Chemical Description, Business Overview and Total Revenue 6.6.3 Cayman Chemical Soybean Trypsin Inhibitor Sales, Revenue and Gross Margin (2015-2020) 6.6.4 Cayman Chemical Products Offered 6.6.5 Cayman Chemical Recent Development 6.7 Worthington Biochemical 6.6.1 Worthington Biochemical Corporation Information 6.6.2 Worthington Biochemical Description, Business Overview and Total Revenue 6.6.3 Worthington Biochemical Soybean Trypsin Inhibitor Sales, Revenue and Gross Margin (2015-2020) 6.4.4 Worthington Biochemical Products Offered 6.7.5 Worthington Biochemical Recent Development 6.8 Geno Technology 6.8.1 Geno Technology Corporation Information 6.8.2 Geno Technology Description, Business Overview and Total Revenue 6.8.3 Geno Technology Soybean Trypsin Inhibitor Sales, Revenue and Gross Margin (2015-2020) 6.8.4 Geno Technology Products Offered 6.8.5 Geno Technology Recent Development 6.9 Abcam 6.9.1 Abcam Corporation Information 6.9.2 Abcam Description, Business Overview and Total Revenue 6.9.3 Abcam Soybean Trypsin Inhibitor Sales, Revenue and Gross Margin (2015-2020) 6.9.4 Abcam Products Offered 6.9.5 Abcam Recent Development

7 Soybean Trypsin Inhibitor Manufacturing Cost Analysis 7.1 Soybean Trypsin Inhibitor Key Raw Materials Analysis 7.1.1 Key Raw Materials 7.1.2 Key Raw Materials Price Trend 7.1.3 Key Suppliers of Raw Materials 7.2 Proportion of Manufacturing Cost Structure 7.3 Manufacturing Process Analysis of Soybean Trypsin Inhibitor 7.4 Soybean Trypsin Inhibitor Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers 8.1 Marketing Channel 8.2 Soybean Trypsin Inhibitor Distributors List 8.3 Soybean Trypsin Inhibitor Customers

9 Market Dynamics 9.1 Market Trends 9.2 Opportunities and Drivers 9.3 Challenges 9.4 Porters Five Forces Analysis

10 Global Market Forecast 10.1 Global Soybean Trypsin Inhibitor Market Estimates and Projections by Type 10.1.1 Global Forecasted Sales of Soybean Trypsin Inhibitor by Type (2021-2026) 10.1.2 Global Forecasted Revenue of Soybean Trypsin Inhibitor by Type (2021-2026) 10.2 Soybean Trypsin Inhibitor Market Estimates and Projections by Application 10.2.1 Global Forecasted Sales of Soybean Trypsin Inhibitor by Application (2021-2026) 10.2.2 Global Forecasted Revenue of Soybean Trypsin Inhibitor by Application (2021-2026) 10.3 Soybean Trypsin Inhibitor Market Estimates and Projections by Region 10.3.1 Global Forecasted Sales of Soybean Trypsin Inhibitor by Region (2021-2026) 10.3.2 Global Forecasted Revenue of Soybean Trypsin Inhibitor by Region (2021-2026) 10.4 North America Soybean Trypsin Inhibitor Estimates and Projections (2021-2026) 10.5 Europe Soybean Trypsin Inhibitor Estimates and Projections (2021-2026) 10.6 Asia Pacific Soybean Trypsin Inhibitor Estimates and Projections (2021-2026) 10.7 Latin America Soybean Trypsin Inhibitor Estimates and Projections (2021-2026) 10.8 Middle East and Africa Soybean Trypsin Inhibitor Estimates and Projections (2021-2026) 11 Research Finding and Conclusion

12 Methodology and Data Source 12.1 Methodology/Research Approach 12.1.1 Research Programs/Design 12.1.2 Market Size Estimation 12.1.3 Market Breakdown and Data Triangulation 12.2 Data Source 12.2.1 Secondary Sources 12.2.2 Primary Sources 12.3 Author List 12.4 Disclaimer

In Order to place the Purchase Query Click Here: https://www.qyresearch.com/settlement/pre/1611144/global-soybean-trypsin-inhibitor-market

About Us:

QY Research established in 2007, focus on custom research, management consulting, IPO consulting, industry chain research, data base and seminar services. The company owned a large basic data base (such as National Bureau of statistics database, Customs import and export database, Industry Association Database etc), experts resources (included energy automotive chemical medical ICT consumer goods etc.

See original here:
Soybean Trypsin Inhibitor Market Brief Analysis and Application, Growth by 2026 | Biological Industries, Thermo Fisher Scientific, Sigma-Aldrich...